Wednesday, October 13, 2021 6:01:44 AM
In sections ...
Related cases/ counter statement -might it be said that Amarin infringement case is related?
Timing of Epadi case ..”disgruntled retail investors” are in fact shareholders in the company who rightly consider that the loss of 7 billion of shareholder value post the district courts decision which was erroneous and based on two studies Mori and K which in the case of Mori has now been clearly demonstrated to have been statistically and fatally flawed as to its conclusion and in the case of K the DC relied on the false testimony of the defence expert supported by the cropping of the K table which if correctly presented would inevitably have caused the DC to reject K as having any part in supporting a conclusion that patents were obvious
“Outrageous abd baseless theories”- the Epadi case is based on the correct scientific consideration of Mori And K and are not theories but represent statements of fact
The defendants apart from through glib and excited rhetoric do not in their brief address any element whatsoever of the matters set out in clear and precise detail within the rule 60 motion - they do not challenge the facts
“No matter the stage of the litigation
Epadi brought its case within the prescribed time limits and expeditiously after the revelation of the statistical falseness of the Mori study being revealed and the K table cropping coming to light and expeditiously following Amarin failing to Perdue a Rule 60 application
The action brought by Epadi could not have been brought a moment sooner than it was
“The courts well reasoned judgement “
Was predicated on reliance for obviouslness upon the Mori study which is completely statistically flawed abd the K study which was misrepresented by the defence expert and his misrepresentation supported by the cropped K table
“Of note -Amarin did not provide any support whether substantive or financial “
The first point to make is that A did not object to the motions. The second point to make is that Epadi case had to be brought because A did not of its own volition pursue such action- it was entirely necessary because of this
A failure to do is not evidence or support for the suggestion of the defendants that these motions are without merit
Epadi is not aware as to why A failed to bring such action - A were at the time perusing other legal proceedings to seek the overturn of the D.C. decision. It is possible to speculate as to what other reasons A had in not bringing this action. The Defendsnts are not privy as to why A did not do so
More to follow
Alm
Recent AMRN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
FEATURED Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • Oct 30, 2024 12:22 PM
FEATURED Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • Oct 30, 2024 9:08 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM
VAYK Clarifies It Has No Business Connection to Persons Under SEC Charge • VAYK • Oct 28, 2024 11:59 AM